Oxford BioMedica PLC (OXBDF)

[marcusl2]

http://www.hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/20.03.18-supply-to-meet-demand.pdf

with the first phase of expansion expected to become operational from 3Q’19.

Additional approvals can be expected within a month given the regulatory timelines experienced for Kymriah in B-ALL.

Furthermore, the footprint of the proposed new facility is sufficiently large to allow the addition of a further three GMP vector manufacturing suites in the future (7 new in total)
The first phase is expected to be completed at the end of 2019, with 50% of the new capacity to be live in 2020. At this point in time, the manufacturing capacity at OXB will be broadly equivalent to one of Lonza’s smaller manufacturing sites. OXB is adopting a modular design approach that will allow further capacity expansion to meet the expected increase in demand in the future. For example, another GMP vector manufacturing suite could be added relatively easily in an unutilised part of the new facility, without causing disruption, for ca.£4m.

(So we can build on further suites on site)

The space available allows flexibility to buy in larger volume bioreactors (up to 2,000l), as suspension culture technology advances.

. Combined, higher-volume suspension cultures and TRiP technology support ‘next generation bioprocessing’, reducing cost of goods and further attracting customers.
Product

However, OXB has been in active communication with US-based venture capital partners, and discussions are ongoing.

Staff up to .500 in 2019

Gross income 86.9 million 2020